- Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
- Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- Supernus Provides Regulatory Update for SPN-830
- Supernus to Participate in Two Upcoming Investor Conferences
- Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
- Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
- Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
- Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
- Supernus Announces Third Quarter 2023 Financial Results
- Supernus to Participate in the Jefferies London Healthcare Conference
More ▼
Key statistics
On Tuesday, Supernus Pharmaceuticals Inc (0LB2:LSE) closed at 31.11, -15.09% below its 52-week high of 36.64, set on May 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 30.70 |
Average volume | 23.00 |
---|---|
Shares outstanding | 54.97m |
Free float | 52.21m |
P/E (TTM) | 1,200.00 |
Market cap | 1.67bn USD |
EPS (TTM) | -0.0152 USD |
Data delayed at least 20 minutes, as of May 07 2024 17:38 BST.
More ▼